If the risk of febrile neutropenia is ≥ 30% (as assessed by neutrophil count < 500 mcL [< 0.5 × 10 9 / L], presence of infection during a previous cycle of chemotherapy, associated comorbid disease, or age > 75), growth factors are indicated (2).